TEST:

Guardant360® Liquid

''Guardant Health, Inc...today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026...New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer companion diagnostic...Findings show how Guardant360 Liquid CDx can expand access to targeted therapies by identifying actionable biomarkers missed by genomic testing''